The Business Of Biotech Podcast

  1. Bio Career Moves With Codagenix's Johanna Kaufmann, Ph.D. 10/11/2023

    On this week's episode of the Business of Biotech, Dr. Johanna Kaufmann gives us an intimate retrospective on her career to date, sharing stories about her rapid ascension from Scientist 1 to executive leadership. We dig into her wild ride through M&A, her time at GSK, and the professional and personal development regimens she subscribes to.

  2. Veteran Advice From The C-Suite With Citius' Leonard Mazur 10/4/2023

    Leonard Mazur has been in the business of biotech for a long, long time, and he has no intention of stopping now. He’s faced challenges won, lost, and ongoing, and he’s willing to share his experiences—from winning FDA approvals to bootstrapping his current effort at Citius Pharmaceuticals—with the transparent confidence of an industry veteran.

  3. Don't Be A D**k With Ochre Bio's Dr. Quin Wills 9/27/2023

    Don't be offended by the title of today's Business of Biotech podcast. Dr. Quin Wills' application of what's become known as "Wheaton's Law" (look it up) is central to the ambitious goals his company, Ochre Bio, is pursuing: pioneering the value of computational biology in large mol discovery and development, putting an end to the global liver disease epidemic, and changing the costly, high-risk approach to clinical trials. On this week's episode, Dr. Wills and I explore how those goals are being addressed despite the challenges they present, and how the company's three guiding principles, don't be a d**k being one of them, align the Ochre team with the mission at hand. 

  4. Pragmatic Computational Biology with Andrew Satz 9/20/2023

    This week's guest on the Business of Biotech, EVQLV's Andrew Satz, says AI and ML in biopharma are like sex in high school. "Many of the people who say they're doing it really aren't, and the one who really are aren't talking about it," he says. So, when it comes to the computational biology buzz, what’s real? What’s hype? What’s yielding benefit and what’s merely vaporware?

  5. Commercial Readiness with Orca Bio's Dan Kirby 9/14/2023

    Orca Bio's Dan Kirby has played a hand in prepping more than a few approved biologic therapeutic candidates for commercialization. Equally important, he knows firsthand what makes or breaks post-approval commercial efforts, having played virtually every role there is to play in drug sales and marketing.

  6. Bio & The Business Of Aging with Life Biosciences' Jerry McLaughlin 9/7/2023

    Core to the clinical-stage biopharma Life Biosciences belief set is that "contrary to popular belief, aging is not caused by random wear and tear, but instead is caused by a discrete set of biological mechanisms that can be targeted therapeutically.”

  7. Fiscal Turnarounds With Protalix's Eyal Rubin 8/30/2023

    Within about five minutes of conversation with Protalix CFO Eyal Rubin, I learned that he doesn’t bite his tongue about the rigors of biotech business and finance management, which is precisely why I’m eager to talk with him on today’s episode of the podcast. From commercialization deals with big pharma to being about $50 million underwater to swatting away the day trading armchair quarterbacks on Stocktwits, Rubin’s seen a few things and he’s developed more than a few opinions.

  8. Building LEO Pharma's U.S. Presence with Brian Hilberdink 8/23/2023

    In many respects, bringing an established foreign biopharma company to the U.S. market is not unlike starting one up from scratch. In other respects, it's even harder. The job's not for the faint of heart, which might be why the Danish company LEO Pharma tapped veteran biopharma leader Brian Hilberdink to lead its U.S. operations.

  9. Managing Momentum With Rezolute Bio's Nevan Charles Elam, JD 8/16/2023

    Since we last spoke in the Spring of 2021, Nevan Charles Elam, JD has managed to advance both of small-but-mighty Rezolute Bio's candidates onto the next phases of their journey. This year, on the back of a $130 million investment, Rezolute Bio is prepping its RZ358 candidate, a monoclonal antibody for congenital hyperinsulinism, for a pivotal phase 3 trial. On this week's episode of the Business of Biotech, we're settling in for an interrogation of Elam on the management principles of maintaining multi-candidate clinical momentum among highly disparate candidates and raising big dollars as a small biotech.

  10. Facing NASH Therapeutic Skepticism With 89bio's Rohan Palekar 8/9/2023

    The non-alcoholic steatohepatitis (NASH) therapeutics market has proven to be an 11/10 on the difficulty scale. Despite billions of big biopharma dollars invested in therapeutic development, and a few close calls, no therapeutics has yet reached the finish line.